Department of Medicine, University of California at San Diego, La Jolla, 92093-0663, USA.
Am J Respir Cell Mol Biol. 2011 Mar;44(3):341-9. doi: 10.1165/rcmb.2010-0001OC. Epub 2010 May 6.
Endotoxin and other immunostimulants ubiquitous in ambient air are potent mucosal adjuvants, yet only a minority of individuals develop aeroallergen hypersensitivities, whereas the majority develop tolerance. These investigations were performed to reconcile this paradox. During initial experiments, mice received a primary series of weekly intranasal OVA immunizations (1(0) vaccination). Selected mice also received intranasal sterile house dust extract (HDE) with each OVA vaccination, at a dose previously found to exert adjuvant activity. A third group of OVA-vaccinated mice received intranasal HDE on a daily basis, but at one seventh the adjuvant dose, beginning 1 week before the first and ending with the last 1(0) OVA vaccination. Mice were then left untreated for 4 weeks, and then received a secondary series of weekly intranasal OVA immunizations with adjuvant doses of HDE (2(0) sensitization). Three weeks later, OVA-specific airway challenges and immune responses were assessed. Analogous experiments were conducted with LPS. Mice receiving daily intranasal HDE or LPS during 1(0) OVA vaccination were highly resistant to 2(0) sensitization, whereas the mice in other experimental groups readily developed Th2-biased airway hypersensitivity. Tolerance was associated with poor OVA-specific CD4 cell proliferation and with local natural T-regulatory cell (Treg) expansion. Finally, Treg depletion by delivery of the anti-CD25 monoclonal antibody during 1(0) vaccination attenuated the tolerogenic effects of daily airway HDE exposures. These studies suggest that regular airway immunostimulant exposures selectively increase local Treg numbers and activity in an antigen-independent manner, thereby promoting the development of aeroallergen tolerance.
内毒素和其他无处不在的环境空气中的免疫刺激剂是有效的黏膜佐剂,但只有少数人会发展为过敏原过敏,而大多数人则会产生耐受性。进行这些研究是为了解决这一矛盾。在最初的实验中,小鼠接受了每周一次的鼻腔内 OVA 免疫接种(1(0) 疫苗接种)。选择的小鼠还在每次 OVA 接种时接受鼻腔内无菌室内尘埃提取物(HDE),剂量为先前发现具有佐剂活性的剂量。第三组接受 OVA 疫苗接种的小鼠每天接受鼻腔内 HDE,但剂量为佐剂剂量的七分之一,从第一次接种前一周开始,最后一次接受 1(0)OVA 疫苗接种。然后,小鼠未经处理 4 周,然后接受每周一次的鼻腔内 OVA 免疫接种,佐剂剂量为 HDE(2(0) 致敏)。三周后,评估了 OVA 特异性气道挑战和免疫反应。类似的实验用 LPS 进行。在 1(0)OVA 疫苗接种期间每天接受鼻腔内 HDE 或 LPS 的小鼠对 2(0)致敏具有高度抗性,而其他实验组的小鼠则容易发展为 Th2 偏向性气道过敏。耐受性与 OVA 特异性 CD4 细胞增殖不良和局部天然 T 调节细胞(Treg)扩增有关。最后,在 1(0)疫苗接种期间通过递送抗 CD25 单克隆抗体耗尽 Treg 会减弱每日气道 HDE 暴露的耐受形成作用。这些研究表明,定期的气道免疫刺激剂暴露以非抗原依赖的方式选择性地增加局部 Treg 数量和活性,从而促进过敏原耐受的发展。